Posted inStock
Apellis stock drops on Astellas drug update
Investing.com — Shares of Apellis Pharmaceuticals (NASDAQ:APLS) fell 8.9% in premarket trading following news that the FDA accepted a revised supplemental application from competitor Astellas Pharma for its eye drug,…